Updates

REF: AGM/INTIMATION/2025-26 Date: September 03, 2026 BSE Limited National Stock Exchange of India Limited 25th Floor, Phiroze Jeejebhoy Towers Exchange Plaza, C-1, Dalal Street, Mumbai 400 001 Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 BSE Code-531146 NSE Code: MEDICAMEQ Sub: Submission of Integrated Annual Report for FY 2025-26 and Notice of the 33rd Annual General Meeting (‘AGM’) of Medicamen Biotech Limited (‘the Company’) to be held through Video Conferencing/Other Audio-Visual Means (“VC/OAVM”) on September 26, 2026 Ref: Regulation 30 and 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) read with circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India Dear Sir/Madam This is in furtherance to our letter dated August14, 2026 wherein the Company had informed that the 33rd AGM of the Company will be held on Saturday, September 26, 2026 at 12:00 Noon (IST) through Video Conferencing/Other Audio Visual Means (‘VC/OAVM’), in accordance, with the relevant circulars issued by Ministry of Corporate Affairs (‘MCA Circulars’). In this regard, we wish to inform the following: 1. Pursuant to the MCA Circulars including General Circular No. 20/2020 dated May 5, 2020 and subsequent circulars, the latest being Circular No. 03/2025 dated September 22, 2025, the Notice of the 33rd AGM along with Integrated Annual Report including the Business Responsibility and Sustainability Report for the financial year 2025-26 (FY 2026) is being sent through electronic mode to all the Members whose email ids are registered with the Company/Registrar and Share Transfer Agent (‘RTA’)/Depository Participant (‘DP’). These documents can be accessed through the following web links and are also enclosed herewith: a. Notice of 33rd AGM: Click here b. Integrated Annual Report FY 2025-26:Click here Further, in compliance with Regulation 36(1)(b) of the Listing Regulations, the Company is also sending a letter to Members whose e-mail ids are not registered with the Company/RTA/DP providing the weblink where the Integrated Annual Report for FY 2026 and the Notice of the 33rd AGM can be accessed on the Company’s website. 2. The Company has provided the facility to its Members to cast their vote electronically, through the remote e-Voting facility (prior to AGM) and e-Voting facility (during the AGM), on all the resolutions set forth in the AGM Notice to the Members, who are holding shares on the Cut-off date i.e. Saturday, September 19, 2026. 3. The Remote e-Voting facility will be available during the following period: Commencement of remote e-Voting Wednesday, September 23, 2026 (09:00 a.m. IST) End of remote e-Voting Friday, September 25, 2026 (05:00 p.m. IST) 4. Detailed instructions for registering email id(s) and e-voting/ attendance at the AGM are given in the notes to the AGM Notice. Kindly take the same on record. Thanking You. Yours Faithfully For Medicamen Biotech Limited Parul Choudhary Company Secretary ACS44157 ANNUAL REPORT 2025-26 MEDICAMEN BIOTECH LIMITED ANNUAL REPORT 2025-26 MEDICAMEN BIOTECH LIMITED GROWING STRONGER REACHING FURTHER MEDICAMEN BIOTECH LIMITED Registered Office Haridwar Unit-I: 86 and 87, Sector-6A, IIE, 1506, Chiranjiv Towe, 43 SIDCUL, BHEL, Ranipur, Nehru Place, New Delhi – 110 019 Haridwar – 249 403, Uttarakhand Tel: 011 4758 9500 Website: www.medicamen.com Bhiwadi Factory Haridwar Unit-II: 84 and 85, Sector-6A, IIE, SP-1192A and B Phase-IV, SIDCUL, BHEL, Ranipur, Industrial Area, Bhiwadi – 301 019, Haridwar – 249 403, Uttarakhand District: Alwar, Rajasthan Across the Pages About Medicamen 2 Business Highlights, 4 2025-26 Product Portfolio 5 Presence 6 Manufacturing Units 7 Chairman’s Message 8 Financial Highlights 10 Leadership and Team 11 weivrevO etaroproC stnemetatS laicnaniF 2-11 Standalone 92 Consolidated 127 stropeR yrotutatS 12-91 Corporate Information 12 Board's Report 13 Management Discussion 65 and Analysis Corporate Governance 69 Report ecitoN 92-163 164-188 GROWING STRONGER REACHING FURTHER Growth is not just about moving ahead. It is about building greater strength, widening the horizon and creating the capabilities to go further. For Medicamen, 2025-26 was a year of progress on each of these fronts. The Company strengthened its oncology division, expanded its presence across priority therapies and leading institutions, and accelerated the growth of Medicamen Lifesciences in the domestic market. At the same time, its international and CDMO initiatives opened new pathways for growth, extending its reach beyond established markets. STRONGER BUSINESSES WIDER REACH NEW POSSIBILITIES Together, these developments are adding greater depth and scale to Medicamen’s business, while building a more resilient platform for the opportunities ahead. Market Capitalisation `302.86 Crores (as of 31 March 2026) CIN L74899DL1993PLC056594 BSE Code 531146 NSE Symbol MEDICAMEQ Bloomberg Code MDCB:IN Dividend Declared Final Dividend of `1/- per equity share (i.e, 10% on the face value of `10/-) AGM Date Saturday, 26 September 2026 AGM Mode Through Video Conference/Other Audio-Visual Means (VC/OAVM) noitamrofnI rotsevnI Scan this QR Code to access the Investor Relations page, or, click on the following link https://www.medicamen.com/ investor/view/8 Disclaimer This document contains statements about expected future events and financials of Medicamen Biotech Limited (‘The Company’), which are ‘forward- looking’. By their nature, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is a significant risk that the assumptions, predictions, and other forward-looking statements may not prove to be accurate. Readers are cautioned not to place undue reliance on forward-looking statements as several factors could cause assumptions, actual future results and events to differ materially from those expressed in the forward-looking statements. Accordingly, this document is subject to the disclaimer and qualified in its entirety by the assumptions, qualifications and risk factors referred to in the Management Discussion and Analysis section of this Annual Report. Corporate Overview Statutory Reports Financial Statements About Medicamen Gaining Value through Focused Growth Medicamen Biotech Limited The Company has three manufacturing (‘Medicamen’ or ‘The Company’) plants, with one USFDA-approved is an integrated pharmaceutical facility, one EU-approved facility and one WHO-GMP-approved facility. enterprise dedicated to delivering Supported by rigorous quality high-quality and affordable management systems, these facilities therapeutics globally. With a enable the Company to serve semi- growing focus on complex regulated emerging markets as well oncology and high-value as highly demanding international general formulation segments, healthcare markets with consistent the Company continues to quality and precision. strengthen its operational footprint across domestic and international markets. Values Our Offerings Quality Cancer Care Anti-Malarials We maintain stringent control systems and procedures to ensure compliance with CGMP standards. Cardiology Vitamins Trusted Partner CNS Antibiotics We build relations that enable us to deliver lasting solutions for the benefit of our customers. We are proud to be trusted by our Diabetology Pain customers and suppliers. 2 Medicamen Biotech Limited Annual Report 2025-26 3 Corporate Overview Statutory Reports Financial Statements Creating Domestic Brand Business International & CDMO Progress Medicamen Lifesciences, a subsidiary established in August 2022, is strengthening Medicamen’s presence in the Indian pharmaceutical market Denmark & Norway through a focused portfolio and expanding prescriber network. Its growing Product registrations secured, with presence across leading pharmacy and institutional channels, together with a commercial supplies initia [Showing first 8,000 characters — download PDF for full document]